The outbreak of coronavirus disease of 2019 (COVID-19) has become a global public health and economic crisis. The advent of hypercoagulability and thrombotic complications can substantially influence the prognosis of COVID-19 patients. In this review, we elaborate on the clinical findings, potential underlying pathogenesis, and therapeutic strategy of hypercoagulability and thromboembolism in COVID-19, particularly focusing on the COVID-19 patients with preexisting digestive hypercoagulability disease.
All Keywords
【저자키워드】 SARS-CoV-2, Coronavirus disease 2019, Inflammatory bowel disease, Thromboembolism, hypercoagulability, 【초록키워드】 COVID-19, coronavirus disease, Pathogenesis, Prognosis, Clinical findings, outbreak, disease, therapeutic strategy, COVID-19 patients, COVID-19 patient, global public health, thrombotic complication, digestive, 【제목키워드】 COVID-19,
【저자키워드】 SARS-CoV-2, Coronavirus disease 2019, Inflammatory bowel disease, Thromboembolism, hypercoagulability, 【초록키워드】 COVID-19, coronavirus disease, Pathogenesis, Prognosis, Clinical findings, outbreak, disease, therapeutic strategy, COVID-19 patients, COVID-19 patient, global public health, thrombotic complication, digestive, 【제목키워드】 COVID-19,